Country: ইস্রায়েল
ভাষা: ইংরেজি
সূত্র: Ministry of Health
CEFTRIAXONE AS SODIUM
TRIMA ISRAEL PHARMACEUTICAL PRODUCTS MAABAROT LTD
J01DD04
POWDER FOR SOLUTION FOR INJ/INF
CEFTRIAXONE AS SODIUM 1 G/VIAL
I.M, I.V
Required
PJSC SIC " BORSHCHAHIVSKIY CPP", UKRAINE
CEFTRIAXONE
Ceftriaxone is indicated for the treatment of the following infections in adults and children including term neonates (from birth): - Bacterial Meningitis - Community acquired pneumonia - Hospital acquired pneumonia - Acute otitis media - Intra-abdominal infections - Complicated urinary tract infections (including pyelonephritis) - Infections of bones and joints - Complicated skin and soft tissue infections - Gonorrhoea - Syphilis - Bacterial endocarditis Ceftriaxone may be used: - For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults - For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III) in adults and children including neonates from 15 days of age. - For pre-operative prophylaxis of surgical site infections - In the management of neutropenic patients with fever that is suspected to be due to a ceftriaxone - susceptible bacterial infection - In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above Ceftriaxone should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum. Consideration should be given to official guidelines on the appropriate use of antibacterial agents.
2022-05-23
CEFTRIAXONE-TRIMA 1 G POWDER FOR SOLUTION FOR INJECTION/INFUSION 1. NAME OF THE MEDICINAL PRODUCT Ceftriaxone-Trima 1 g 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial of Ceftriaxone-Trima 1 g contains 1.196 g of ceftriaxone sodium, equivalent to 1 g of ceftriaxone Excipient with known effect: Sodium 1 g vial contains 3.6 mmol (or 83 mg) of sodium per vial. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for solution for injection/infusion. Almost white or yellowish crystalline powder, slightly hygroscopic. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ceftriaxone-Trima 1 g is indicated for the treatment of the following infections in adults and children including term neonates (from birth): - Bacterial meningitis - Community acquired pneumonia - Hospital acquired pneumonia - Acute otitis media - Intra-abdominal infections - Complicated urinary tract infections (including pyelonephritis) - Infections of bones and joints - Complicated skin and soft tissue infections - Gonorrhoea - Syphilis - Bacterial endocarditis Ceftriaxone-Trima 1 g may be used: - For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults. - For treatment of disseminated Lyme borreliosis (early [stage II] and late [stage III]) in adults and children including neonates from 15 days of age . - For pre-operative prophylaxis of surgical site infections. - In the management of neutropenic patients with fever that is suspected to be due to a ceftriaxone-susceptible bacterial infection. - In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Ceftriaxone-Trima 1 g should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum (see section 4.4). Consideration should be given to official guidelines on the appropriate use of antibacterial agents. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The dose dep সম্পূর্ণ নথি পড়ুন